FACULTAD DE CIENCIAS BIOMÉDICAS Y DE LA SALUD

Fakultatea

Foto de FACULTAD DE CIENCIAS BIOMÉDICAS Y DE LA SALUD

Foto de Centre Antoine Lacassagne

Centre Antoine Lacassagne

Niza, Francia

Centre Antoine Lacassagne-ko ikertzaileekin lankidetzan egindako argitalpenak (5)

2020

Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial
Journal of Clinical Oncology

2015

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial
The Lancet Oncology, Vol. 16, Núm. 16, pp. 1700-1710
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
New England Journal of Medicine, Vol. 372, Núm. 8, pp. 724-734

2013

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
The Lancet Oncology, Vol. 14, Núm. 6, pp. 461-471

2005

Cancer-related anemia: Pathogenesis, prevalence and treatment
Oncology